Market Overview

Perrigo Confirms First to File Patent Challenge for Generic Version of Testosterone Gel 1.62%

Related PRGO
Top Performing Industries For November 24, 2014
Perrigo Acquires Omega Pharma For $4.5 Billion Euro
Horizon Inks $660M Reverse Merger With Ireland's Vidara (Fox Business)

Perrigo Company (Nasdaq: PRGO) announced that it has filed with the U.S. Food and Drug Administration (FDA) an Abbreviated New Drug Application for testosterone gel 1.62% and that it has notified AbbVie Inc., the owner of the Reference Listed Drug of its filing.

On February 15, 2013, the Unimed Pharmaceuticals subsidiary of AbbVie and Besins Healthcare filed suit against Perrigo in the United States District Court for the District of Delaware, alleging patent infringement. This action formally initiates the process under the Hatch-Waxman Act. Perrigo believes that it is a first filer for this opportunity, entitling it to 180 days of generic exclusivity.

Androgel® 1.62% (testosterone gel 1.62%) is indicated to treat males who have low or no testosterone. Annual sales were approximately $680 million annually, as measured by Wolters Kluwer Health.

Perrigo's Chairman and CEO Joseph C. Papa stated, "This filing is another example of our investment in new products and continued focus on bringing extended topicals to market. As always, Perrigo is committed to making quality healthcare more affordable for our customers and consumers."

Posted-In: News FDA

 

Related Articles (PRGO)

Around the Web, We're Loving...

Get Benzinga's Newsletters